A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy

Anti-CD20 treatment represents a therapeutic benefit for patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing patients. Among them, the combination of anti-CD20 and IL-2 that induces T cell response has been hampered by the expansion of FoxP3(+) Tr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Casadesús, Ana Victoria, Deligne, Claire, Diallo, Béré Kadjdiatou, Sosa, Katya, Josseaume, Nathalie, Mesa, Circe, León, Kalet, Hernández, Tays, Teillaud, Jean-Luc
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7458652/
https://ncbi.nlm.nih.gov/pubmed/32923126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1770565
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados